156.47
-2.60 (-1.63%)
| Previous Close | 159.06 |
| Open | 160.00 |
| Volume | 112,294 |
| Avg. Volume (3M) | 506,867 |
| Market Cap | 4,470,204,928 |
| Price / Earnings (TTM) | 85.35 |
| Price / Earnings (Forward) | 74.07 |
| Price / Sales | 6.05 |
| Price / Book | 6.86 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 |
| Profit Margin | 6.67% |
| Operating Margin (TTM) | 13.30% |
| Diluted EPS (TTM) | 1.75 |
| Quarterly Revenue Growth (YOY) | 24.50% |
| Quarterly Earnings Growth (YOY) | 138.60% |
| Total Debt/Equity (MRQ) | 4.61% |
| Current Ratio (MRQ) | 7.13 |
| Operating Cash Flow (TTM) | 130.25 M |
| Levered Free Cash Flow (TTM) | 62.72 M |
| Return on Assets (TTM) | 3.04% |
| Return on Equity (TTM) | 8.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | Inspire Medical Systems, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 1.05% |
| % Held by Institutions | 116.73% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 236.00 (Baird, 50.83%) | Buy |
| Median | 200.00 (27.82%) | |
| Low | 174.00 (Wells Fargo, 11.21%) | Hold |
| Average | 201.57 (28.83%) | |
| Total | 5 Buy, 2 Hold | |
| Avg. Price @ Call | 154.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 06 May 2025 | 236.00 (50.83%) | Buy | 161.88 |
| JP Morgan | 06 May 2025 | 195.00 (24.63%) | Buy | 161.88 |
| Morgan Stanley | 06 May 2025 | 200.00 (27.82%) | Buy | 161.88 |
| Wells Fargo | 06 May 2025 | 174.00 (11.21%) | Hold | 161.88 |
| Keybanc | 21 Apr 2025 | 216.00 (38.05%) | Buy | 144.70 |
| Stifel | 21 Apr 2025 | 175.00 (11.85%) | Hold | 144.70 |
| RBC Capital | 15 Apr 2025 | 215.00 (37.41%) | Buy | 146.24 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 May 2025 | Announcement | Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight |
| 05 May 2025 | Announcement | Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook |
| 29 Apr 2025 | Announcement | Inspire Medical Systems, Inc. to Present at the BofA Securities 2025 Health Care Conference |
| 21 Apr 2025 | Announcement | Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors |
| 01 Apr 2025 | Announcement | Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025 |
| 06 Mar 2025 | Announcement | Inspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |